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Abstract
The present study used in vitro and in vivo stroke models to demonstrate the safety,
efficacy, and mechanism of action of adult human bone marrow-derived NCS-01
cells. Coculture with NCS-01 cells protected primary rat cortical cells or human neural progenitor cells from oxygen glucose deprivation. Adult rats that were subjected
to middle cerebral artery occlusion, transiently or permanently, and subsequently
received intracarotid artery or intravenous transplants of NCS-01 cells displayed
dose-dependent improvements in motor and neurological behaviors, and reductions
in infarct area and peri-infarct cell loss, much better than intravenous administration.
The optimal dose was 7.5 × 106 cells/mL when delivered via the intracarotid artery
within 3 days poststroke, although therapeutic effects persisted even when administered at 1 week after stroke. Compared with other mesenchymal stem cells, NCS-01
cells ameliorated both the structural and functional deficits after stroke through a
broad therapeutic window. NCS-01 cells secreted therapeutic molecules, such as
basic fibroblast growth factor and interleukin-6, but equally importantly we observed
for the first time the formation of filopodia by NCS-01 cells under stroke conditions,
characterized by cadherin-positive processes extending from the stem cells toward
the ischemic cells. Collectively, the present efficacy readouts and the novel filopodiamediated mechanism of action provide solid lab-to-clinic evidence supporting the
use of NCS-01 cells for treatment of stroke in the clinical setting.
KEYWORDS

cell loss, cell transplantation, cerebral ischemia, cytokines, functional recovery, infarct, motor
deficits
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1 | I N T RO D UC T I O N
Significance statement
The present study recognizes critical translational gaps in

death among adult populations around the world,1 significantly cost-

stem cell transplant dose, route, and timing after stroke,

ing the United States billions of dollars each year.2 Tissue plasminogen

and acknowledges solid safety profile of mesenchymal

activator (tPA) is the sole FDA-approved drug to treat acute ischemic

stem cells. The study tested a human bone marrow-derived

stroke, which accounts for roughly 87% of all strokes.3,4 tPA is most

mesenchymal stem cell line called NCS-01 in oxygen glu-

effective when administered intravenously (IV) within 4.5 hours of

cose deprivation and middle cerebral artery occlusion

stroke onset,4 but is toxic outside this therapeutic window, causing

models, which revealed the optimal dose of 7.5 × 106

hemorrhagic transformation.4 Mechanical thrombectomy serves as an

cells/mL via the intracarotid artery within 3 days post-

alternative treatment for ischemic stroke, but it too encounters chal-

stroke. Secretion of cytokines, specifically bFGF and IL-6,

lenges such as a limited therapeutic window (6-24 hours post

and filopodia formation, are potential mechanisms. Based

stroke),5 bleeding, coagulation abnormalities, and intracranial hemor-

on these preclinical data, the FDA in July 2019 approved

rhage.6 Since most stroke patients do not have access to tPA therapy

intracarotid NCS-01 cell transplantation in ischemic stroke

or qualify for mechanical thrombectomy within the limited therapeutic

patients.

windows, novel treatments are warranted. Cell-based regenerative
medicine has emerged as a safe and effective experimental treatment
for stroke and has reached clinical trials.
The central nervous system has long been considered as incapable
of regeneration. Stem cell research has challenged this paradigm with
compelling evidence of exogenous and endogenous repair processes.

7

Transplantation of embryonic, fetal, umbilical, amnion, and induced
pluripotent stem cells shows functional improvements in experimental
8,9

stroke.

Adult bone marrow-derived stem cells, such as endothelial

progenitor cells, hematopoietic, and mesenchymal stem cells (MSCs),
have expedited the translation of lab-to-clinic stem cell therapy due
to their logistical ease in isolation and amplification, and being relatively free from ethical concerns.

10,11

MSCs have been explored as

transplantable donor cells for many experimental models of neurological diseases,12,13 such as Parkinson's disease,14–16 amyotrophic lateral
17–19

sclerosis,

20,21

Alzheimer's disease,

22–28

and stroke.

Cell replace-

ment was initially implicated in MSCs' therapeutic effects, yet with
only modest graft survival despite robust functional outcomes,29 the
currently accepted mechanism of action involves bystander repair
processes primarily via stem cell-secreted therapeutic factors.30–33
This promising preclinical evidence, as well as solid safety record in
treating hematological diseases, provides concrete grounds for clinical
translation of MSC therapy in stroke. However, two clinical trials
examining MSCs upheld their safety, but did not reveal efficacy.34,35
IV transplantation of autologous bone marrow MSCs at 4 weeks following stroke reputedly demonstrated enhanced neurological outcomes, yet these functional improvements diminished by 12 months
after transplantation.34 An inconsistent adherence may have contributed to strict doses and therapeutic time windows. For example, preclinical investigations employ approximately 4 million cells for IV

preclinical studies demonstrating neuroprotective effects, provides a
solid rationale for testing the efficacy of an MSC line toward advancing stem cell therapy in stroke.
In identifying transplantable bone marrow-derived MSCs for clinical application, we used lab-to-clinic translational research criteria,
namely the cells need to be of human origin, clinical grade, ample supply, and with well-defined phenotypic markers. To this end, the adult
bone marrow-derived NCS-01 cells satisfy all these criteria. From the
basic science research standpoint, transparency of the phenotypic
characteristics of NCS-01 cells should allow the cells' reproducibility
and direct comparisons with other MSC transplantation studies. From
the clinical research view, the human, clinical grade and ample supply
should aid in optimization of the envisioned human clinical product
and circumvent inherent translational problems when testing rodent
MSCs as transplant material. Accordingly, the present study employed
highly translational stroke paradigms to evaluate the safety, efficacy,
and mechanism of action of NCS-01 cells, using the in vitro oxygen
glucose deprivation (OGD) model, and the in vivo transient and permanent middle cerebral artery occlusion (MCAO) models. Optimal
route of administration, and a side-by-side comparison with the current standard MSCs, allowed us to directly assess the therapeutic
effects of NCS-01 cells in ameliorating stroke-induced behavioral and
histological deficits, eventually serving as a guide for the envisioned
clinical trial design. Based on the preclinical data presented here, we
recently received in early July 2019 the FDA's approval to proceed
with the clinical application of intracarotid artery (ICA) transplantation
of NCS-01 cells in ischemic stroke patients.

administration for a 250 g stroke rat, corresponding to 840 million
cells in a human of 75 kg, whereas clinical trials have employed doses

2 | METHODS

well below those deemed optimal in preclinical animal models.34,35
This lack of translation of optimal laboratory parameters may explain

The data that support the findings of this study are available from

these failed clinical efforts despite overwhelming experimental evi-

the corresponding author upon reasonable request. This series of

dence.23 Recognizing these critical translational gaps, while acknowl-

highly translational studies utilized NCS-01 cells, which are human

edging the long-standing safety profile and the abundance of

bone marrow-derived MSCs produced by Progenitor Cell Therapy
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(Mountain View, California). The release criteria included phenotypic

equilibrated with continuous flow of 95% N2 and 5% CO2 gas for

characterization of these cells via fluorescence-activated cell sorting,

15 minutes. After this equilibrium, the chamber was sealed and placed

indicating that these cells are CD105+, CD73+, CD90+, CD34−,

into the incubator at 37 C for 90 minutes. Thereafter, OGD was ter-

CD45−, and CD14−. Subsequent release criterion added the capacity

minated by adding glucose to the culture medium and returning the

of these cells to secrete high amounts of basic fibroblast growth fac-

cultures to the standard 20% O2 and 5% CO2 incubator. A 1- or

tor (bFGF) and interleukin-6 (IL-6). Cell viability of NCS-01 cells was

2-hour period of “reperfusion” in standard medium and normoxic con-

confirmed at least >85% prior to starting each experiment. Engraft-

dition was allowed.

ment was also confirmed for each transplant experiment and revealed
modest graft survival, with graft persistence almost nondetectable by
sue or tumor formation was detected in any study.

The viability of primary rat cortical cells or human neural progenitor
cells was evaluated immediately after OGD (no NCS-01 cells added)

2.1 | In vitro studies
2.1.1 | Cell culture

and at 5 hours after OGD using standard 3-(4,5-dimethylthiazolyl-2)2,5-diphenyltetrazolium bromide (MTT) and trypan blue exclusion
assays. Following reperfusion, reduction of MTT by cellular dehydrogenases was used as a measure of mitochondrial activity as previously

Mixed cultures of gestation age E18 primary cortical neurons and
astrocytes were initially used as host cells (CAMBREX, Maryland). To
further enhance the translational relevance of the study, subsequent
cell culture studies used human neural progenitor cells (Neuromics,
Maryland) to better mimic the human condition. Immediately after
thawing, cells (4 × 104 cells/well) were seeded and grown in 96-well
plate coated by poly-L-lysine in Neurobasal media (GIBCO, California)
containing 2 mM L-glutamine, 2% B27 (GIBCO) and 50 U/mL penicillin and streptomycin for 7-10 days at 37 C in humidified atmosphere
containing 5% CO2. To further probe the mechanism of action of

described.37 In addition, trypan blue (0.2%) exclusion method was
conducted and mean viable cell counts were calculated in four randomly selected areas (1 mm2, n = 10) to reveal the cell viability after
the ischemic-reperfusion condition. Briefly, within 5 min after adding
trypan blue, we digitally captured under microscope (×200) 10 pictures
(approximately 100 cells per picture) for each condition, then randomly selected 5 pictures, and counted the number of cells for each
individual treatment condition. Normalized cell viability was calculated
from the following equation: viable cells (%) = [1.00 − (Number of
blue cells / Number of total cells)] × 100.38

NCS-01 cells, a vis-a-vis in vitro efficacy test was performed comparing the targeted cell viability and NCS-01 cells' filopodia formation
when cocultured with a specific neural cell lineage, including primary

2.1.4 | Cytokine analysis

rat cortical neurons (CAMBREX), primary rat astrocytes (Fisher), and

Cytokines were measured in the supernatant of cultured cells at

primary rat endothelial progenitor cells (EPCs) (Harvard, Massachu-

5 hours after OGD using commercially available ELISA kits to detect

setts). Neurons were seeded and grown in culture as above. Astro-

initially human brain derived neurotrophic factor (BDNF), beta-nerve

cytes were seeded and grown in high glucose DMEM (Fisher), 10%

growth factor (β-NGF), IGF-1, VEGF, bFGF, and IL-6, but subsequently

fetal bovine serum (Neuromics), and 1% penicillin and streptomycin.

just focused on bFGF, and IL-6, which were chosen based on our pilot

EPCs were seeded and grown in endothelial cell growth basal

studies demonstrating that the expression levels of these two cyto-

medium-2 (Lonza, CH), 5% fetal bovine serum, 0.2 mL hydrocortisone,

kines were consistently upregulated in the supernatant of cultured

2 mL human bFGF, 0.5 mL vascular endothelial growth factor (VEGF),

NCS-01 cells. Briefly, the supernatant was collected from the culture

0.5 mL R3 insulin-like growth factor-1 (IGF-1), 0.5 mL ascorbic acid,

medium of NCS-01 cells and transferred into a centrifuge tube

0.5 mL human epidermal growth factor, and 0.5 mL gentamicin-

which was then centrifuged at 1500 rpm for 10 minutes at 4 C.

amphotericin-B (GA-1000) (Lonza, CH). Neurons, astrocytes and EPCs

Thereafter, aliquots of the supernatant were collected and stored at

were likewise seeded and grown in a 24-well plate (coated with poly-

−80 C until use. Concentrations of cytokines were detected using

D-lysine for neurons only) for 7-10 days at 37 C in humidified atmo-

ELISA kits (Abcam, United Kingdom) according to the manufacturer's

sphere containing 5% CO2.

instructions.

2.1.2 | OGD model

2.1.5 | Filopodia formation assay and IL-6 and bFGF
treatment

The cultured primary rat cortical cells or human neural progenitor cells
were exposed to OGD as described previously36 with few modifica-

This set of experiment was designed to reveal a potential regenerative

tions. Briefly, the culture medium was replaced with a glucose-free

mechanism mediating the therapeutic effects of NCS-01 cells on

Earle's balanced salt solution with the following composition: 116 mM

ischemic cells. Primary rat cortical neurons (which may also include a

NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 1 mM NaH2PO4, 26.2 mM

small percentage of glial cells) were subjected to OGD-reperfusion

NaHCO3, 0.01 mM glycine, 1.8 mM CaCl2, and pH adjusted to 7.4.

paradigm as described above. Next, NCS-01 cells were cocultured

Cultured cells were placed in humidified chamber, and then

with the host cells for 3 hours at 37 C using a two-chamber system
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MCAO, animals were re-anesthetized, and reperfusion commenced

ferent distances (ranging from 0 to 2.04 mm) above host cells which

with the withdrawal of the nylon suture. We have standardized the

were seeded on the lower chambers containing DMEM medium and

MCAO model, with stroke animals showing ≥80% reduction in

poly-L-lysine coated glass coverslips. The lower chambers that con-

regional cerebral blood flow (CBF) during the occlusion period as

tained host rat cells only (since the upper chambers small pore size did

determined by laser Doppler (Perimed, Periflux System 5000). For

not allow migration of human NCS-01 cells toward the lower cham-

baseline regional CBF measurement, the laser Doppler probe was

bers, as confirmed by lack of HuMito stained cells in these chambers)

placed over the right frontoparietal cortical area supplied by the MCA.

were then processed for immunocytochemical analyses of formation

We also found no significant differences in physiological parameters,

of human filopodia using N-cadherin antibodies (Abcam). Double

including PaO2, PaCO2, and plasma pH measurements. Rats that

labeling with a neuronal cell death marker using propidium iodide

reached the 80% regional CBF reduction and >75% biased swing

(Abcam) staining was also carried out to assess any interaction

activity (see below) during occlusion were enrolled in these studies.

between NCS-01 cell-derived filopodia formation and primary rat cor-

Thereafter, incisions were closed, and animals were allowed to

tical neuron viability. A control group was also established comprising

recover from anesthesia. Whereas for transient MCAO, the nylon

cortical neurons that were not subjected to OGD nor received any

suture blocked the MCA for 60 minutes, for permanent MCAO, the

treatment. In the additional mechanistic probe test, primary rat corti-

nylon suture was not removed.

cal neurons, primary rat astrocytes, and primary rat EPCs were subjected to OGD and reperfusion as described above. 1 ng/mL each of

2.2.3 | Treatment

IL-6 and bFGF was administered to half of the host cells after undergoing OGD and reperfusion, such that one group received cell media

At specified time points after MCAO, animals were randomly assigned

only (OGD only control), another group received IL-6 + bFGF, a third

to receive ICA (via the internal carotid artery) transplants of either

group received the NCS-01 cell coculture at a distance of 0.8 mm, and

saline/fibroblast cells (placebo) or NCS-01 cells. Since the animals

a final group received IL-6 + bFGF and the NCS-01 cell coculture at a

received right MCAO, animals also received infusion of saline/fibro-

distance of 0.8 mm. After 12 hours at 37 C, MTT assay and N-

blast cells or stem cells into the right ICA. Our ipsilateral ICA proce-

cadherin staining were performed.

dure also allowed infusion of saline/fibroblast cells and NCS-01 cells



in permanent MCAO. Cell doses were based on pilot studies that
showed efficacy without adverse effects (ie, microembolism). Based

2.2 | In vivo studies

on our experience, efficacy with ICA may be obtained at a lower dose

2.2.1 | Subjects

of stem cells compared to IV route of delivery. Infusion of stem cells
was performed via an autoinjection pump (Harvard Apparatus) at a

All experimental procedures were approved by the University of

rate of 1 mL/min. A PE-10 polyethylene catheter connected to a 25G

South Florida Institutional Animal Care and Use Committee. Male

butterfly needle and a 1-mL syringe was inserted into the stump of

Sprague-Dawley rats (8 weeks old, n = 3-10 per treatment group)

right ECA through an incision on the vessel and was tightened to the

were housed under normal conditions, with two animals housed per

ECA by sutures. The catheter was positioned forward into ICA and

cage (20 C temperature, 50% relative humidity, and 12-hour light/

passed the pterygopalatine artery, the extracranial branch of ICA, in

dark cycle). The rats had free access to water and food. All necessary

order to enhance the delivery of the saline/fibroblast cells or stem

precautions were taken in order to reduce pain and suffering of the

cells toward the brain. The catheter was filled with saline/fibroblast

animals throughout the study. Animals were closely checked twice

cells or stem cells to prevent formation of potential harmful air bub-

per day. All studies were performed by personnel blinded to the treat-

ble. The syringe was also filled with saline/fibroblast cells or stem

ment condition.

cells. After dosing, the needle was removed without any flush and the
CCA was closed with sutures to prevent any bleeding, and the skin

2.2.2 | MCAO model

wound reclosed with surgical clips. NCS-01 cell doses ranged from

As previously described, stroke surgery was performed using the

concentration. In subsequent studies, the ICA route was vis-à-vis

MCAO technique.28,39,40 Animals were anesthetized with a mixture of

compared with IV administration (via the jugular vein).

7.5 × 104 to 3.75 × 107 total in 0.1 to 5 mL with 7.5 × 106 cell/mL

1% to 2% isoflurane in nitric oxide/oxygen (69%/30%) via a face
mask, and body temperature was maintained at 37 ± 0.3 C during the
surgical procedures. A midline skin incision was made in the neck with

2.2.4 | Behavioral tests

subsequent isolation of the left common carotid artery, the external

All investigators testing the animals were blinded to the treatment

carotid artery (ECA), and internal carotid artery. Thereafter, a 4-0

condition. Each rat was subjected to a series of behavioral tests to

monofilament nylon suture (15.0-17.0 mm) was advanced from the

reveal motor and neurological performances at different time points

common carotid artery bifurcation until it blocked the origin of the

before and after stroke and transplantation of NCS-01 cells. The tests

MCA. The skin incision was closed with surgical clips. Animals were

included the modified Bederson neurological test (composite score of

allowed to recover from anesthesia during MCAO. At 1 hour after

contralateral hind limb retraction, beam walking ability, and bilateral
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sodium citrate solution at pH 6 for 40 minutes at 80 C for antigen

Body Swing Test (EBST). The Bederson neurological test is an evalua-

retrieval. Next, samples were blocked for 60 minutes at room temper-

tion of the animal's sensorimotor function, which consists of three dis-

ature with 8% normal goat serum (Invitrogen, California) in PBS con-

tinctive phases, performed over approximately 10 minutes per rat.

taining 0.1% Tween 20 (PBST; Sigma). Sections were then incubated

Each phase of the test was conducted sequentially and was each

overnight at 4 C with mouse anti-HuMito (Abcam) with 4% normal

scored 0 to 3. These three evaluations were: 1. contralateral hind limb

goat serum. Thereafter, the sections were washed five times for

retraction; 2. bilateral forepaw grasp; and 3. beam walking ability.

10 minutes in PBST and soaked in 4% normal goat serum in PBST

Contralateral hind limb retraction measured the ability of the animal

containing corresponding secondary antibodies, goat anti-rabbit IgG-

to replace the hind limb after it was displaced laterally by 2 to 3 cm.

Alexa Fluor 594 (red; 1:500; ThermoFisher Scientific) for 90 minutes.

Grades were as follows: 0 for immediate smooth replacement, 1 for

Finally, sections were washed five times for 10 minutes in PBST and

slow replacement, 2 for partial rigid replacement, and 3 for no replace-

three times for 5 minutes in PBS, cover-slipped with Vectashield har-

ment. Bilateral forepaw grasp measured the ability of a rat to hold

dset with DAPI (H-1500, Vector Laboratories, California). All sections

onto a 2-mm diameter steel rod. Grade 0 was used for rats with nor-

were examined using a confocal microscope (Zeiss). Control studies

mal forepaw grasping behavior, 1 for rapid grasping but with rigidity,

included exclusion of primary antibody substituted with 5% normal

2 for slow grasping with rigidity, and 3 for a rat unable to grasp with

goat serum in PBS. No immunoreactivity was observed in these

the forepaw. Beam walking ability used a beam apparatus that was

controls.

80 cm long with a flat surface of 2-4 cm width resting at least 40 cm
above the table/surface top on two poles. The animal was placed at
one end of the beam then the ability to traverse the beam and reach

2.2.6 | Histology

the other end was assessed. The grades were as follows: 0 for a rat

Alternate brain tissue sections were processed for Nissl staining,

that easily traversed the beam, 1 if the rat slowly traversed the beam,

which was performed with 0.1% cresyl violet solution (Sigma-Aldrich)

2 for partially traversing the beam but falls off, and 3 for a rat unable

using a standard protocol to evaluate the peri-infarct injury of our

to stay on the beam for 10 seconds. The scores from all three tests

MCAO model. From each perfused brain, six coronal sections

were added to give a total neurologic deficit score (maximum possible

between the anterior edge and posterior edge of the MCAO infarct

score is 9 with mean composite neurologic score of 3). A score of 2.5

area were collected and processed for Nissl staining. Every sixth coro-

was set as a criterion to be considered a “stroke” animal. EBST is a

nal tissue section was chosen at random to quantify cell survival in

measure of asymmetrical motor behavior that does not require animal
training or drug injection.41 The rats were held, in the vertical axis,
approximately 1 in from the base of its tail and then elevated to an
inch above the surface on which it has been resting. The frequency
and direction of the swing behavior were recorded for over 20 tail ele-

the peri-infarct area. Brain sections were examined using a light
microscope (Keyence). Neuronal survival in the peri-infarct area of the
brain was quantified using a computer-assisted image analysis system
(NIH Image Software) and was expressed as a percentage of the ipsilateral hemisphere compared to the contralateral hemisphere.

vations. A swing was counted when the head of the rat moved more
than 10 from the vertical axis to either side. Normally, intact rats display a 50% swing bias, that is, the same number of swings to the left
and to the right. A 75% swing bias toward one direction was used as
criterion of motor deficit.41 The total number of swings made to the
biased side was added per group and divided by the n, providing the
average number of swings per treatment group.

2.2.7 | Statistical analyses
The data were evaluated statistically using two-way ANOVA followed
by post hoc Bonferroni corrected pairwise comparison t-tests. Statistical significance was preset at P < .05 (Statview). The KolmogorovSmirnov test was performed to assess normality and the resulting
values were less than 5% of the critical values.

2.2.5 | Euthanasia and perfusion
Under deep anesthesia, rats were euthanized for immunofluorescent

3 | RESULTS

and protein analysis. For immunofluorescent analysis, briefly, animals
were perfused through the ascending aorta with 200 mL of cold PBS,
followed by 200 mL of 4% paraformaldehyde in phosphate buffer
(PB). Brains were harvested and postfixed in the same fixative for
72 hours, followed by 30% sucrose in PB until completely sunk. Series

3.1 | Study 1
3.1.1 | Higher doses of NCS-01 cells increase
primary rat cortical cell viability

of coronal sections were cut at a thickness of 40 μm using a cryostat

Dosage evaluation is necessary to determine optimal safety and effi-

and stored at −20 C. Brains were harvested and coronal sections

cacy of NCS-01 cells. Dose-response in vitro studies entailed adding

were collected at a thickness of 2 mm using a brain matrix.

different doses of NCS-01 cells to primary rat cortical neurons and

Staining for human mitochondria-positive cells was conducted on

astrocytes (host cells) after 2-hour reperfusion, with dosages

every 1 of 6 sections, 40 mm thick in brain. All sections were washed

expressed as percent ratio of NCS-01 cells to host cells. Each well

three times for 5 minutes in PBS. Sections were incubated with saline

contained 4 × 104 host cells. Doses of 1 × 104, 2 × 104, 3 × 104,
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4 × 104, 8 × 104, or 1.6 × 105 cells/well, equating to 25%, 50%, 75%,

similar pattern (Figure 1B,D). Dosages of 25%, 50%, 75%, 100%, and

100%, 200%, or 400% of host cell numbers, were used and compared

200% NCS-01 cells produced approximately onefold increments in

to contemporaneous OGD controls with 0% NCS-01 cells. An addi-

MTT absorbance over 0% NCS-01 cells or OGD controls (P < .01,

tional low dosage of 2 × 103 cells/well or 5% of host cell numbers

P < .001, P < .0001). The 400% NCS-01 cell wells exhibited the most

was subsequently assessed. Cell viability of host cells was assessed

benefit, displaying a twofold increase in mitochondrial activity over

immediately after OGD and at 5 hours after OGD. Trypan blue was

the OGD control (P < .0001).

used as an indicator of host cell death while MTT assay assessed metabolic or mitochondrial activity of the cells.

Based on these in vitro findings, NCS-01 cells exerted host cell
death rescue as assessed by trypan blue and MTT assays. Results suggest that a significantly robust therapeutic effect required at least a
1:1 ratio of NCS-01 cells to primary rat cortical neurons and astro-

pan blue (Figure 1A,C), 5% NCS-01 cell wells exhibited no appreciable

cytes. Collectively, these promising results of the in vitro dose-

difference over the OGD control. Twenty-five percent of NCS-01 cell

response experiments provided the impetus to examine NCS-01 cells

wells minimally rescued against host cell death compared to the OGD

under in vivo stroke paradigms.

control (P < .05). Fifty percent and 75% NCS-01 cell wells showed
modest, nonsignificant increases in cell viability over the OGD control
(P > .05). Ratios of 1:1, 2:1, and 4:1 of NCS-01 cells to host cells produced the largest increases in rescue of host cell death, with all at
least 20% greater than their OGD controls (P < .05, P < .01,

3.1.2 | Route type favors ICA over IV cell delivery
for reducing infarct area, but both routes comparably
improve neurological function

P < .0001) (Figure 1C). No significant difference was observed

Based on the above in vitro dose finding study, in vivo experiments

between these three higher doses. The greatest increase was found in

were conducted to find the best route to most effectively deliver

the 200% NCS-01 cell wells, which were approximately 35% greater

NCS-01 cells into the target lesion. This study compared ICA and IV

than the OGD control (P < .0001). In addition, MTT assay revealed a

routes in a 2 × 2 between groups design. Groups of three (for IV

F I G U R E 1 NCS-01 cells protect cultured primary rat cortical cells against oxygen glucose deprivation (OGD). Host cell viability was measured
at different dosages relative to the number of host cells. Cell survival was assessed via trypan blue for control (0%) and at NCS-01 cell amounts
ranging from 5% to 100%. Ratios of 1:4 and 1:1 displayed the greatest survival (#P < .05 vs 0%) (A). Cell survival was also assessed via trypan blue
for control (0%) and higher amounts of NCS-01 cells, ranging from 100% to 400% (*P < .01, #P < .001 vs 0%) (C). All three of the higher ratios
exhibited robust survival in comparison to the control, *P < .01. Mitochondrial activity was measured via MTT assay for the control and for NCS01 cell amounts ranging from 25% to 100% (*P < .01, **P < .001, #P < .0001 vs 0%) (B) and from 100% to 400% (*P < .05, #P < .0001 vs 0%) (D),
with another control. All ratios improved absorbance, with 4:1 providing the best results
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NCS-01 cells rescued against host cell death in direct relation to
the number of NCS-01 cells added (Figure 1). When measured by try-
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administration) or six (for ICA administration) male rats were sub-

(P < .05, P < .0001). This measure was unaffected by route type, pre-

jected to 1 hour transient MCAO and were treated with either saline

sumably indicating that the clinical measurements may not always

or 7.5 × 106 NCS-01 cells in 1 mL. Animals were followed-up for up

reflect enhanced neurological function in all affected brain regions.

to 7 days post-transplantation.

Taken together, these results suggest that ICA delivery of NCS-01

IV-delivered or ICA-delivered NCS-01 cells provided substantial

cells produced better stroke outcomes than IV delivery, at least in one

neurologic and pathologic benefit as compared to saline when admin-

aspect of brain damage. In addition, these results provided evidence

istered in rats with transient MCAO (Figure 2A,B). Furthermore, at

that the therapeutic effects of NCS-01 cells seen in vitro translated to

7 days poststroke, the ICA-administered NCS-01 cells reduced the

functional benefits in the in vivo stroke model.

infarct size almost twice as smaller as that seen with IV administration
(P < .0001). Thus, ICA delivery was more effective than the IV route in
ameliorating brain damage. In addition, neurological deficit was
decreased with either route of NCS-01 cell administrations compared

3.1.3 | ICA infusion of NCS-01 cells poses no greater
risk than no treatment or placebo

to saline-treated stroke rats. By day 7, NCS-01 cell treatment

After determining logistical factors such as dosage and route, it is

groups scored approximately 40% lower than the saline groups

important to address safety concerns when considering eventual

Downloaded from https://academic.oup.com/stcltm/article/9/2/203/6406779 by University of South Florida user on 21 June 2022

F I G U R E 2 Intracarotid artery (ICA) transplants of NCS-01 cells attenuate stroke-induced behavioral and histological deficits. Route
efficacy was measured by comparing changes in infarct volume and neurological deficit after administration of either NCS-01 cells or saline
(A, B). Both routes of NCS-01 cell administration decreased both infarction (*P < .05, #P < .0001) and neurological deficit scores (*P < .05,
#P < .0001 vs saline) as compared to saline, but a difference was observed between ICA and IV delivery only in measures of infarct volume.
In this case, ICA-administration was more effective than IV-administration. No difference was observed between routes for neurological
deficit. In addition, two dosages of NCS-01 cells, saline, or no infusion (MCAO only) displayed no substantial differences when using cerebral
blood flow assessment as a measure of safety indicating that ICA NCS-01 cells did not alter blood flow and was safe (albeit did not lead to
overt embolism) (C)
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were subjected to 1 hour transient MCAO and divided into groups

3.1.4 | Doses as low as 7.5 × 105 NCS-01 cells
substantially reduce infarct volume and improve
neurological function

receiving ICA administration of 5 × 107 NCS-01 cells in 5 mL,

Based on the previous measures, it was determined that ICA adminis-

clinical translation of NCS-01 cells. To evaluate ICA administration
safety, CBF assessment was conducted. Male rats (n = 6 per group)

1 × 107 NCS-01 cells in 5 mL, 5 mL of saline, or no infusion (MCAO
only). The CBF was measured by Doppler at baseline (before MCAO),

tration is the better route than IV to deliver more cells to the target
lesion. This measure also found a benefit of NCS-01 cells for neurological function and infarction volume in MCAO rats. To further

4 hours, 12 hours, and 24 hours post dosing. Perfusion units

advance these findings, cell dosages were evaluated using the ICA

were calculated and were displayed as percentages. CBF was not

administration. In the first investigation, groups of six rats were sub-

decreased by ICA administration of 1 or 5 mL of NCS-01 cells in the

jected to 1 hour transient MCAO and were given 7.5 × 105,

stroke model when compared to the no infusion group and the saline

7.5 × 106, or 3.75 × 107 NCS-01 cells. To avoid confounding NCS-01

group (Figure 2C). This suggests that ICA administration of NCS-01

cell dose with NCS-01 cell concentration effects, cells were adminis-

cells may be just as safe as no infusion, when operationalized by CBF

tered as a fixed cell concentration of 7.5 × 106 cells/mL. Thus, the

assessment.

administration volumes were 0.1, 1.0, or 5.0 mL, respectively. Groups

F I G U R E 3 A mid-range dose of NCS-01 cells offers the greatest value while maximizing effects. Having established efficacy, route, and
safety, multiple measures manipulating dosage were conducted. High doses, ranging from 7.5 × 105 to 3.5 × 107 NCS-01 cells, yielded roughly
equivalent effects on both infarct volumes and longitudinal (28 days) neurological deficit (*P < .05, #P < .0001 vs saline) (A, B). Following these
results, a lower set of dosages was tested, ranging from 7.5 × 104 to 7.5 × 105 NCS-01 cells (*P < .05, #P < .0001 vs fibroblast) (C, D). Among
these, 7.5 × 105 NCS-01 cells yielded the best results for both reduction of infarction volume and longitudinal (7 days) neurological deficit,
although lower doses still exerted partial therapeutic effects when compared to fibroblast placebo
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treated with NCS-01 cells exhibited reduced infarct volumes that
were less than a quarter of the size of the saline groups (P < .0001)
(Figure 3A,B). Additionally, by day 28, neurological deficit scores of
groups treated with NCS-01 cells were approximately reduced by half
compared to the scores of the saline groups (P < .0001). No significant
differences were observed between the three NCS-01 cell treatment

3.2 | Study 2
3.2.1 | NCS-01 cell treatment improves stroke
outcomes after permanent MCAO, but more
effectively promotes functional benefits in
transient MCAO
To optimize the clinical target, it is necessary to examine the func-

More importantly, a dose of 3.75 × 10 NCS-01 cells was well toler-

tional benefits of NCS-01 cells in different disease conditions. Thus,

ated in rats via the ICA route up to 28 days post-MCAO. These results

the therapeutic effects of ICA-delivered NCS-01 cells were compared

provided further evidence of the ameliorative effects of NCS-01 cells

between transient MCAO and permanent MCAO (n = 6 per group). At

in vivo and suggest that dosages as low as 7.5 × 10 cells could pro-

24 hours postocclusion, both conditions received either 1 mL saline

vide therapeutic effects.

(placebo) or 7.5 × 106 NCS-01 cells in 1 mL. Overall, results show

7

5

To further advance the application of NCS-01 cells to the clinic, a

behavioral and histological improvement in both MCAO paradigms

second experiment was conducted to establish a minimum effective

after 28 days. NCS-01 cells reduced infarct volume by approximately

in vivo dose. Various amounts of NCS-01 cells as well as fibroblast

60% to 70% (P < .0001) (Figure 4A). Additionally, infarct volume was

cells were used to reduce infarct volume. Four groups of six rats were

more greatly reduced in the transient MCAO than in the permanent

subjected to 1 hour transient MCAO and were then infused with

MCAO (P < .001). For neurological deficit score, the benefit was two-

either 7.5 × 105 NCS-01 cells in 0.1 mL, 2.5 × 105 NCS-01 cells in

to threefold greater (depending mainly on the poststroke observation

0.03 mL, 7.5 × 104 NCS-01 cells in 0.1 mL, or 7.5 × 106 rat fibroblast

time) with ICA NCS-01 cells in the transient MCAO than in the per-

cells in 1 mL. Efficacy varied according to dosage (Figure 3C,D). All

manent MCAO (P < .01, P < .001). The time course of neurological

NCS-01 cell-treated groups displayed significantly lower infarct vol-

deficit showed steady improvement over the 28 days poststroke,

umes when compared to the fibroblast group (P < .0001). For neuro-

averaging between 11% lower during this period for permanent +

logical function, stroke animals that received NCS-01 cell dosages of

saline treated animals to 67% lower for transient + NCS-01 cell-

2.5 × 105 cells and 7.5 × 105 cells exhibited significantly lower deficit

treated animals (Figure 4B). Thus, under these pathological conditions,

scores than the fibroblast group (P < .05, P < .0001). Additionally, the

NCS-01 cell treatment was more effective in transient MCAO than

7.5 × 10 NCS-01 cells in 0.1 mL dosage were far more effective than

permanent MCAO, although it still had some ameliorative effect in

the other two NCS-01 cell dosages for both reducing infarct volume

permanent MCAO. It should be noted that the transient occlusion

and improving neurological function. Thus, 7.5 × 105 NCS-01 cells in

model mimics the situation in which a stroke patient experiences suc-

0.1 mL could anchor further studies as a standard minimum dosage

cessful revascularization procedure, such as tPA treatment or clot

for stroke models.

removal via thrombectomy. The permanent occlusion mimics the

5

F I G U R E 4 NCS-01 cells confer therapeutic effects in both transient and permanent middle cerebral artery occlusion (MCAO) models, but
more potently improve functional outcomes in ischemic-reperfused stroke animals. Quantitative analysis of the infarction volume after 28 days in
saline and NCS-01 cells treated groups for transient and permanent occlusion. NCS-01 cells decreased infarction volume nearly threefold
compared to saline treatment. NCS-01 cell treatment revealed a greater reduction in infarction volume for the transient occlusion than the
permanent occlusion condition (*P < .001 vs NCS-01 permanent, #P < .0001 vs saline) (A). Mean neurological score across 28 days for saline and
NCS-01 cell treated groups for transient and permanent occlusion. NCS-01 cells improved neurological function in both the transient and
permanent conditions, with a gradual increase across the 28 days (*P < .05, #P < .0001 vs saline, $P < .01, &P < .001 vs NCS-01 permanent) (B).
NCS-01 cell treatment preferentially promoted greater histological and neurological improvements in animals exposed to transient MCAO than
those subjected to permanent MCAO
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F I G U R E 5 NCS-01 cells remain a viable treatment option days after stroke. Quantitative analysis of the infarct volume across NCS-01 cell treatment
groups. A reduction in infarction size was observed in all NCS-01 cell groups compared to the saline group. NCS-01 cell treatment was most effective in
decreasing infarct volume when administered 1 or 3 days poststroke, but infarct reduction was still determined at least up to 7 days post-middle cerebral
artery occlusion (MCAO) (*P < .05, #P < .0001 vs saline) (A, E) (*P < .05 vs NCS-01 1 week, #P < .0001 vs saline) (C). Scores reflecting neurological
function in saline and NCS-01 cell treatment groups. NCS-01 cells improved neurological scores across all treatment groups compared to saline, with the
most improvement at administration 1 day post-MCAO (*P < .05, #P < .0001 vs saline, $P < .0001 vs NCS-01 1 week) (B, D, G). Host cell survival in the
ipsilateral (ipsi) and contralateral (contra) peri-infarct area across NCS-01 cell treatment groups at 28 days post-MCAO. All NCS-01 cell groups exhibited
increased cell survival in their ipsilateral peri-infarct area (closer to the cell counts in their contralateral peri-infarct area) compared to the saline group
(*P < .05, #P < .0001 vs each contra) (F). Initiation of NCS-01 cell treatment beyond 3 days following stroke moderated the functional outcomes
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situation in which a stroke patient neither received tPA nor under-

first experiment examined the timing of cell delivery between 3 and

went thrombectomy, possibly because the 4.5 hours time window

24 hours poststroke. The placebo group was dosed with 1 mL saline

had elapsed. This occurs in over 90% of all stroke cases.42

at 24 hours post-MCAO. All animals were assessed for neurological
function up to day 7 and were sacrificed on day 7. The second experi-

3.2.2 | NCS-01 cell treatment remains effective even
when initiated at 1 week post-MCAO, but most
effective when started at 3 days or earlier

ment aimed to examine a lengthened time window by comparing the
timing of cell delivery at 24 hours to 1 week (7 days) post-transient
MCAO. Placebo groups were dosed with saline at 24 hours or 7 days
poststroke. All animals were assessed for neurological function up to
day 28 and were sacrificed on day 28. Finally, the third experiment

is the optimal therapeutic window. Accordingly, three experiments

was conducted to further investigate the therapeutic window

assessed the effect of the timing of cell delivery in the transient

between day 1 and day 7. Rats subjected to 1 hour transient MCAO

MCAO model using the same dose of cells (7.5 × 106 cells in 1 mL) as

were administered either 1 mL saline at 24 hours or 1 week post-

described above, but with treatment initiation ranging from 3 hours to

MCAO or 7.5 × 106 NCS-01 cells in 1 mL at 1, 3, 5, or 7 days post-

1 week post-transient MCAO. Rats were treated with NCS-01 cells

MCAO. All animals were assessed for neurological function up to day

(n = 6-7) or saline (n = 3) and were followed for up to 28 days. The

28 and were sacrificed on day 28.

F I G U R E 6 NCS-01 cells
enhance cell survival, reduce
infarction volume, and secrete
cytokines greater than Li cells
in vitro and in vivo. Trypan blue
assay revealed increased in vitro
host cell viability by lot 18 of
NCS-01 cells, lot 19 of NCS-01
cells, and Li cells following
oxygen glucose deprivation
(OGD) (*P < .001 vs OGD only,
#P < .05 vs Li cells) (A) compared
to ambient condition (control).
Both lots of NCS-01 cells
expressed a near fourfold
elevation in IL-6 and bFGF over
the Li cells (*P < .0001 vs OGD
only, #P < .0001 vs Li cells) (B, C).
Lot 19 of NCS-01 cells increased
in vivo host cell survival and
dramatically reduced infarct
volume by ~60% at 7 days
poststroke compared to the Li
cells (*P < .05 vs Li cells,
#P < .0001 vs saline) (D, E)
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All NCS-01 cell treatment groups significantly improved over the

saline group, but this effect was attenuated for rats treated more than

saline groups on all test outcomes by day 28 or even at earlier time points

3 days post-MCAO. Taken together, the data showed that delivery of

(Figure 5). Infarct volumes (Figure 5A,C,E) varied between approximately

NCS-01 cells ameliorated brain damage and neurological deficit, but that

60% and 80% reduction in all NCS-01 cell treatment groups compared to

delaying treatment after 3 days post-MCAO may not provide as much

saline placebos (P < .05, P < .0001). The greatest reductions were found

functional benefits. This time-dependent therapeutic outcome of NCS-

in rats treated with NCS-01 cells at day 1 and day 3 poststroke

01 cells is a significant finding as it suggests the ideal clinical target would

(P < .0001). While still significant, infarct reduction was somewhat atten-

likely be patients less than 3 days after onset of ischemic stroke.

uated for rats treated with NCS-01 cells more than 3 days post-MCAO.
A similar pattern of results was observed in neurological deficit scores
ment groups over the saline group, but this improvement was again
slightly attenuated in rats treated more than 3 days post-MCAO
(P < .05, P < .0001). Lastly, the third experiment also measured host cell
survival in the contralateral (not directly affected by MCAO) and ipsilat-

3.3 | Study 3
3.3.1 | Other MSCs (Li cells) and NCS-01 cells
display comparable therapeutic effects on host cell
viability

eral (directly affected by MCAO) peri-infarct area (Figure 5F). Again, all

In an effort to determine whether NCS-01 cells performed equally or

NCS-01 cell treatment groups exhibited better host cell survival than the

better than other MSCs, we initially embarked on in vitro tests of

F I G U R E 7 NCS-01 cells improve
behavioral and neurological outcomes
better than Li cells and saline. Motor
function evaluated by the Elevated Body
Swing Test (EBST) (A), contralateral hind
limb retraction (B), bilateral forepaw
grasp (C), and beam walking ability
(D) (*P < .0001 vs Li cells, #P < .0001 vs
saline). NCS-01 cell treatment displayed
improved behavioral function compared
to the Li cells or saline. Stroke rats
treated with NCS-01 cells demonstrated
reduced neurological deficits, nearly half
that compared to the Li cells and saline,
across 7 days (*P < .0001 vs Li cells,
#P < .0001 vs saline) (E)
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(Figure 5B,D,G). Neurological function improved in all NCS-01 cell treat-
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efficacy comparing NCS-01 cells and Li MSCs, which were prepared
as described elsewhere.43 Culture wells containing 4 × 104 human
neural progenitor cells were subjected to OGD, then lot 18 or lot
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3.3.2 | NCS-01 cells produce greater amounts of IL-6
and bFGF in vitro
Additionally, potential mechanisms of action for the neurorestorative

19 of NCS-01 cells were added to the host cell wells. Both lots of

effects of NCS-01 cells on cultures of primary rat cortical neurons and

NCS-01 cells all and Li cells rescued against OGD-induced human host

astrocytes were explored. In the brain, MSCs may secrete trophic fac-

cell death as measured by trypan blue assay (Figure 6A).

tors and cytokines such as BDNF, β-NGF, IGF-1, VEGF, bFGF, and IL-
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FIGURE 8

Legend on next page.
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6. Since these trophic factors and cytokines have the potential to res-

benefits of NCS-01 cells over Li cells, this NCS-01 cell population,

cue cells against the deleterious effects of ischemic insult, a prelimi-

defined by the selected manufacturing process, is a unique donor cell

nary test was performed by assaying concentrations of these factors

population for transplantation therapy. Combining these in vivo

in the OGD model with commercially available ELISA kits. A 1:1 ratio

observations with the previous in vitro data, as well as the results of

of NCS-01 cells to primary rat cortical neurons and astrocytes was

studies 1 and 2, presents a compelling case for declaring safety and

used in the wells. Both lots of NCS-01 cells and Li cells increased

efficacy of NCS-01 cells in treating ischemic stroke.

bFGF and IL-6 (P < .0001) (Figure 6B,C), but none of the other tested
trophic factors (BDNF, β-NGF, IGF-1, and VEGF) were detected.
These findings suggest that IL-6 and bFGF may be the mechanisms of
action behind the amelioration observed after in vitro MSC treatment.
Furthermore, NCS-01 cells produced approximately four times as

Following OGD and reperfusion (Figure 8A), primary rat cortical cells

much IL-6 and bFGF compared to Li cells (P < .0001), indicating that

were cocultured with NCS-01 cells at different distances ranging from

NCS-01 cells exhibited distinct phenotypes and that these specific

0 mm (direct contact) to 2.04 mm (Figure 8A'). Cultures were stained

cytokines were closely associated with the more potent effects of

with propidium iodide to reveal cell viability and N-cadherin to detect

NCS-01 cells than Li cells. Additionally, NCS-01 cell lot 18 and lot

filopodia (Figure 8B-E'). Imaging revealed the presence of filopodia

19 produced identical results, providing quality assurance that the

extending from NCS-01 cells to ischemic cells. Quantitative analyses

same optimized manufacturing process can produce the same cell

detected maximal (about 85% normal levels) rescue of cell viability

population for treating stroke.

and mitochondrial activity from direct contact of NCS-01 cells with
primary rat cortical cells compared to the cells exposed to OGD

3.3.3 | NCS-01 cells produce better therapeutic
effects as assessed by host cell survival, infarction
volume, and neurological function in vivo than Li cells

treated with “non-stem cells” (Figure 8F,G). The two closer distances
(1.68 and 1.80 mm), and, to a lesser degree, the two farther distances
(1.92 and 2.04 mm), also significantly improved cell viability and mitochondrial activity compared to the non-stem cell condition. Taken

The preliminary results from the preceding in vitro experiment moti-

together, these results indicate direct cell-to-cell contact as optimally

vated us to pursue in vivo assessments. Rats (n = 6 per group) were

effective but suggest the potential to achieve equally robust ameliora-

subjected to transient MCAO, and then treated with either saline, Li

tive effects against OGD via indirect long distance rescue via filopodia

cells, or lot 19 NCS-01 cells. Animals were assessed for neurological

formation (Supplemental Figure S2).

function up to day 7 and were sacrificed on day 7. Treatment effects

In order to probe the exact role of IL-6, bFGF, and NCS-

were assessed with host cell survival, infarction volume, and neurolog-

01-derived filopodia in the rescue of different types of host cells, an

ical deficit tests.

additional measure was performed by exposing primary cortical neu-

NCS-01 cells, but not Li cells, rescued against in vivo host cell

rons, primary rat astrocytes, and primary rat EPCs to OGD and reper-

death by ameliorating ischemia-induced brain damage with conse-

fusion and treating with cell media only (OGD only control), IL-6

quent ~60% reduction in infarction (P < .0001) (Figure 6D,E). In addi-

+ bFGF, NCS-01 cell coculture, and a combination of IL-6 + bFGF and

tion, as a consequence of ameliorating ischemia-induced brain

NCS-01 cell coculture. MTT assay reveals that compared to OGD

damage, NCS-01 cells reduced neurological deficit by half (P < .0001).

only, all treatments improved mitochondrial activity in a similar pat-

Again, the same therapeutic effect was not seen with Li cells

tern among cell types, with the greatest activity in the groups treated

(Figure 7). Based on the observed in vivo functional and histological

with NCS-01 cell coculture only and IL-6 + bFGF only (Figure 8H).

F I G U R E 8 NCS-01 cells, in part, employ filopodia-mediated long distance rescue of cultured primary rat cortical cells against oxygen glucose
deprivation (OGD). Primary rat cortical cells were subjected to OGD and reperfusion then cocultured with NCS-01 cells at different distances, as
depicted by procedural timeline and diagram (A and A0 ). Propidium iodide and N-cadherin staining was conducted for the different distances:
(B and B0 ) 1.68 mm, (C and C0 ) 1.80 mm, (D and D0 ) 1.92 mm, and (E and E0 ) 2.04 mm. Propidium iodide staining (red) reveals fewer dead primary
rat cortical cells (indicated by red color) at closer distances than at farther distances between upper and lower chambers (B-E). N-cadherin
staining (green) indicates the presence of filopodia extending from NCS-01 cells (B0 -E0 ) Scale bar = 50 μm. Quantitative analysis of primary rat
cortical neurons reveals that cell viability correlates inversely with increased distance between NCS-01 cells and primary rat cortical neurons,
when measured by trypan blue (TB) assay (F). Similarly, MTT assay reveals that greater mitochondrial activity correlates inversely with greater
distance between NCS-01 cells and primary rat cortical neurons (G). Significance depicted as a-d at P < .05, a: greater than OGD only and all
treatment groups; b: greater than all groups except control, non-OGD group; c: greater than OGD only and 1.92 and 2.04 mm groups; d: greater
than OGD only (F, G). Additionally, primary rat cortical neurons, primary rat astrocytes, and primary rat EPCs were subjected to OGD and
reperfusion then treated with IL-6 + bFGF and/or cocultured with NCS-01 cells at 0.8 mm distance. MTT assay displays greatest mitochondrial
activity in all cell types when cocultured with NCS-01 cells only or treated with IL-6 + bFGF only (*P < .05, #P < .01, &P < .001, $P < .0001) (H).
Moreover, N-cadherin staining demonstrates no significant difference in filopodia formation in the two cocultured groups and a similar pattern
among different cell types (I)
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3.3.4 | NCS-01 cells may rescue primary rat cortical
cells via filopodia formation
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Neurons display the greatest recovery and are the only cell types to

transient MCAO model by using the same optimal effective dose of

exhibit a slight but significant difference between IL-6 + bFGF treat-

cells (7.5 × 106 cells in 1 mL) as described above but delivered at vary-

ment only and NCS-01 cell coculture only, with the latter performing

ing time points from 3 hours to 1-week post-MCAO. The data showed

slightly better than the former treatment (P < .05). There was no sig-

that the delivery of NCS-01 cells within 3 days post-MCAO appears

nificant

difference

between

IL-6 + bFGF-mediated

and

to produce maximal therapeutic effects against MCAO, but that
delaying treatment beyond 3 days post-MCAO, although still effec-

the combined treatment groups, while significantly improved com-

tive, may not provide robust functional benefits. Altogether, these

pared to OGD only, performed substantially worse than either of their

results suggest that the relatively early (less than 3 days) administra-

respective stand-alone groups in every case (P < .01, P < .001,

tion of NCS-01 cells in transient MCAO corresponded to the most

P < .0001), with the minor exception of astrocytes treated with IL-6

responsive stroke population to this cell therapy. However, even

+ bFGF and those treated with combined, which did not differ signifi-

1 week after transient MCAO or with permanent occlusion, NCS-01

cantly (P > .05). Furthermore, across all three neural cell lineages, N-

cells still produced meaningful functional recovery. Such wide thera-

cadherin staining indicates 35% to 55% increments in fluorescence inten-

peutic window, if at all an indication of the stroke prognosis, suggests

sity in stand-alone NCS-01 cell coculture or combined treatment com-

that NCS-01 cells may provide a clinically practical treatment option

pared to OGD only, indicating filopodia formation accompanied the

for individuals who could not avail of tPA and thrombectomy.

improved cell viability and mitochondrial activity in these treatments

The third study was conducted to evaluate the neurorestorative

(Figure 8I). The observed increment in N-cadherin staining did not signifi-

properties of NCS-01 cells compared to other MSCs (Li cells)

cantly differ between NCS-01 cell coculture only and combined treat-

employed for cell therapy in stroke. in vitro results showed that both

ment, suggesting similar robust filopodia formation in both treatments.

cell types were able to rescue against OGD-induced host cell death;

Overall, these results bolster our claim that improvements in mitochon-

however, NCS-01 cells increased cytokine (IL-6 and bFGF) release

drial activity via IL-6 and bFGF release and filopodia formation may be

more than threefold compared to Li cells. This indicates that NCS-01

the primary modes of action of NCS-01 cells' rescue of host cells.

cells phenotypically differ from Li cells, even though both are characterized as MSCs. More importantly, during the in vitro studies, two
different lots of NCS-01 cells produced identical results, hence equiv-

4 | DISCUSSION

alence of these two cell lots was achieved with the same optimized
The present study assessed the potential of NCS-01 cells as a cell-

manufacturing process. Furthermore, comparison between neurons,

based therapy for stroke by conducting a large series of experiments

astrocytes, and EPCs generally revealed similar patterns of NCS-01

distributed in three major translational studies. In the first study, we

cell culture-mediated and IL-6 + bFGF-mediated improvements in

evaluated the efficacy, safety, and mechanism of action of NCS-01

mitochondrial activity, supporting potential modes of action for NCS-

cells in standard in vitro and in vivo models of ischemic stroke. Ini-

01's rescue of host cells in vitro. Subsequent in vivo studies demon-

tially, we showed that NCS-01 cells rescue ischemic cells in a dose-

strated that at 24 hours postocclusion, the ICA infusion of NCS-01

dependent manner in the OGD model. Consequently, we observed

cells, but not Li cells, ameliorated brain infarction and improved neu-

upregulated levels of bFGF and IL-6 in the supernatant of cultured

rological deficits. While Li cells may promote therapeutic effects at a

NCS-01 cells, implicating therapeutic molecule secretion as a mecha-

higher dose, when using the same doses for both MSCs, NCS-01 cells

nism mediating the cells' functional effects. in vivo results showed

outperformed the Li cells in efficacy outcomes.

that ICA cell delivery produced a significant dose-dependent reduc-

Finally, we observed for the first time a novel mechanism involv-

tion in infarct size more effectively than IV, possibly due to its capac-

ing filopodia formation in stem cells under stroke conditions. That

ity to deliver more cells, and likely therapeutic molecules, into the

stem cells may propel cell processes in long distances toward the

ischemic brain. The effective dosage was 7.5 × 10 cells in 1 mL. The

ischemic cells suggests the potential for transplanted cells to engraft

ICA cell delivery route was safe as evidenced by no observable alter-

in a conducive environment remote from the injured tissue, but still

ations in the CBF and absence of microembolic events.

rescue ischemic cells. Filopodia formation has been previously

6

The second study was designed to assess the disease condition

observed in neuroprotective action by Rho kinase inhibition on

(transient or permanent MCAO) and therapeutic window in the

organotypic hippocampal slices against in vitro ischemia.44 Similarly,

in vivo model to gain insights into the clinical target population. The

overexpression of transmembrane glycoprotein CD44 in vitro pro-

results revealed that ICA delivered NCS-01 cells ameliorated that

motes the elongation, spread, and number of filopodia of cultured

stroke-induced behavioral and histological impairments associated

neural precursor cells, while in vivo accelerates the transendothelial

with both transient and permanent MCAO, but the functional

migration and facilitates the invasion of certain perivascular sites.45

improvements in the stroke animals with transient ischemia was two-

Filopodia formation and cell motility, especially transendothelial

to threefold greater than those with permanent occlusion, suggesting

migration, may be facilitated by adhesion molecules, such as Ninjurin

that this therapy would provide more beneficial effects in stroke

1,46 and transcription factors, including serum response factor.47

patients who were successfully revascularized either by tPA or

Understanding the putative role of these transmembrane glycopro-

thrombectomy. The therapeutic window was then evaluated in the

teins, adhesion molecules, and regulatory factors may improve

Downloaded from https://academic.oup.com/stcltm/article/9/2/203/6406779 by University of South Florida user on 21 June 2022

NCS-

01-mediated improvements for astrocytes and EPCs. Interestingly,

218

KANEKO ET AL.

filopodia formation, as well as the resulting therapeutic outcome of

stand as potent transplantable cells with robust and innovative neuro-

NCS-01 cells in stroke.

protective properties for stroke therapy.

Stroke is one of the main causes of disability among adults world-

Despite our extensive study designs and findings, there are certain

wide, with risk factors such as aging, hypertension, hyperglycemia,

limitations in the present study. In particular, future studies may consider

diabetes mellitus, and obesity.48,49 The only FDA-approved drug is

using large animal models, such as porcine and/or nonhuman primate, to

tPA with limited treatment window and high risk of hemorrhagic

better mimic the human clinical pathologies (ie, white matter injury) and

transformation; hence, there is a significant need for finding a novel

to further elucidate the current optimal dose, treatment timing, and route

treatment for stroke. Recently, stem cell therapy has emerged as a

of administration of NCS-01 cells. In addition, since NCS-01 cells are

promising experimental treatment, even reaching clinical trials, for

derived from human cells and would be used for humans, the current

possibly due to the grafted

human-to-rat paradigm may not fully capture the envisioned human-to-

cells' bystander effects such as secretion of growth factors and cyto-

human clinical product. Another limitation is our relatively young stroke

kines associated with neurogenesis, angiogenesis, vasculogenesis, and

animals did not exhibit comorbidities associated with stroke, warranting

mitochondrial repair.48,49,51,52 Here, we demonstrated the appealing

the need to test this cell therapy in a stroke model with comorbidity fac-

therapeutic properties of NCS-01 cells, namely cell secretion of bFGF

tors such as aging and hypertension.53 Furthermore, while the secretion

and IL-6, and filopodia extension in rescuing ischemic cells.

of bFGF and IL-6 coupled with the filopodia formation accompanied the

neurological diseases, including stroke,

The present study revealed many novel observations regarding

therapeutic effects of NCS-01 cells, further manipulation of these phe-

the use of NCS-01 cells for stem cell therapy in stroke. First, we

notypic functions (eg, upregulating or downregulating cytokine release,

showed the safety and efficacy profile of NCS-01 cells, supporting the

and facilitating or inhibiting filopodia formation) may reveal more

cells' potential use as a therapeutic option for stroke. NCS-01 cells

detailed brain repair machinery of this cell therapy.54 Another limitation

rescued cell death, decreased infarct size, and improved neurological

is suggested by the marked disparity between the size of the effects

outcomes after stroke. Second, we identified the minimal optimal dos-

observed in vivo and in vitro. That the in vitro effects paled in compari-

age and demonstrated that ICA route of delivery is safe and effective.

son with the in vivo effects when analyzing individual cell lineages may

We detected that there was no change in blood flow in association

be partially explained by the overall effects of NCS-01 on multiple cell

with the ICA delivery. Furthermore, ICA enhanced the delivery of

phenotypes (neurons, astrocytes, and EPCs), reminiscent of the in vivo

NCS-01 cells to the brain at the same time lowering the effective

neurovascular unit, indicating a multipronged therapeutic mechanism.

dose, further improving the safety profile of the cells. Third, we dem-

Moreover, that the combination of exogenously administered IL-6 and

onstrated that NCS-01 cells are not only effective at reducing infarct

bFGF and NCS-01 cell transplantation did not lead to additive or syner-

volume and improving neurological score at early therapeutic window

gistic effects, and instead tapered the functional improvements com-

(hours after stroke) but also can be extended into days poststroke.

pared to stand-alone treatments may be due to redundant therapeutic

The observed functional benefits persisted long after the administra-

signaling pathways solicited by NCS-01 cells, IL-6, and bFGF, suggesting

tion of NCS-01 cells, indicating robust and stable therapeutic out-

that overloading the system with mere neuroregenerative cytokines

comes. This set of data supports the notion that NCS-01 cells could

does not necessarily equate to enhanced therapeutic outcomes. NCS-01

be used to treat a large number of stroke patients ranging from time

cells' ability to interact with the microenvironment niche, via the cells'

of admission to days during poststroke stabilization. We also demon-

filopodia formation, may allow a reciprocal and regulated modulation of

strated that NCS-01 cells are beneficial for either transient or perma-

the cytokine secretion toward neuroregeneration. Finally, although solid

nent occlusion MCAO paradigms. This supports the use of NCS-01

safety record of MSCs is documented in hematological indications, addi-

cells even for stroke patients who might have missed the opportunity

tional studies may be warranted to address the cells' high proliferative

to receive revascularization procedures such as tPA or endovascular

capacity.50,54,55 Notwithstanding these scientific limitations, these trans-

interventions. Finally, we provided mechanism-based evidence that

lational studies formed the key material of an IND package that was

NCS-01 cells released significantly higher levels of cytokines bFGF

deemed by the FDA as sufficient to grant approval in July 2019 to pro-

and IL-6, clearly distinguishing them from routinely harvested MSCs.

ceed with the clinical trial of NCS-01 cells in ischemic stroke patients.

The pioneering observation of formation of long processes of

In conclusion, the foregoing studies provide insights into the efficacy

filopodia extending from NCS-01 cells toward ischemic cells opens

and mechanisms of NCS-01 cells in treatment of ischemic injury in both

new avenues of research for engineering stem cells designed to propel

in vitro and in vivo rat models (Graphical Abstract). We demonstrated

cell processes to bridge the gap between normal and pathologic (ie,

that NCS-01 cells were able to effectively improve motor and neurologi-

ischemic) tissues. Because the ischemic tissue limits cell survival of

cal behaviors by significantly reducing the infarct area and cell loss in the

exogenous and endogenous stem cells, the neighboring tissues adja-

neighboring peri-infarct region, possibly via secretion of therapeutic mol-

cent to the core or peri-infarct area may be conducive for stem cell

ecules and our pioneering observation of filopodia formation in stem

survival. Although direct cell-to-cell contact between stem cells and

cells. Although our study showed that NCS-01 cells secreted bFGF

ischemic cells was shown optimal, NCS-01 cells' potential to form

and IL-6 in the present OGD in vitro condition, additional cytokines

filopodia over long distances from the spared tissue to the ischemic

and cell-surviving factors may be secreted since NCS-01 cells likely

area may represent a novel repair mechanism allowing graft-induced

will adjust their secretory among other phenotypic functions in response

remote regeneration of ischemic cells. Taken together, NCS-01 cells

to the dynamic brain microenvironment under in vivo stroke setting.
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Additionally, direct cell-to-cell contact, including filopodia interacting
with other protrusive cell membranes may be required for the observed
therapeutic activities. The ICA infusion appeared to improve cell delivery
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to the ischemic brain due to its capacity to directly deliver the highest
number of cells to the lesion area without losing a high percentage of cell
concentration to other circulatory areas. We further demonstrated that
NCS-01 cells maintained a therapeutically active state under a dosedependent mechanism both in vitro and in vivo paradigms. The therapeutic window indicated that even though the best time to administer
still recognized when administered at 1 week after MCAO. Compared
with other MSCs, NCS-01 cells ameliorated both neurostructural and
functional deficits after stroke through a broad therapeutic window. Collectively, these translational observations provided solid lab-to-clinic evidence supporting NCS-01 cell therapy for stroke in the clinical setting.

ACKNOWLEDGMENT
The authors thank the entire Borlongan Neural Transplantation Laboratory for excellent technical assistance.

CONF LICT OF IN TE RE ST
Y.K. declared employment and stock ownership with the University of
South Florida. T.N.C. declared consultant/advisory role and patent holder
with KM Pharmaceutical Consulting LLC. M.K. declared consultant consultant/advisory role, patent holder and stock ownership in KM Pharmaceutical Consulting LLC. C.V.B. declared employment with the University of
South Florida; patent holder with Sanbio Inc, Athersys, Saneron, Astellas;
consultant/advisory role with KMPHC, Astellas, Asterias, Chiesi Pharmaceuticals, Sanbio Inc,; research funding from Astellas, Asterias, International Stem Cell Corp, Saneron, NIH and stock ownership with Sanbio Inc.
The other authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
Y.K., J.-Y.L., N.T., J.P.T., T.L., E.R., S.-J.Y.: experimental work, collection
and/or assembly of data, data analysis and interpretation, manuscript writing; B.B.: experimental work, collection and/or assembly of data, data analysis and interpretation, manuscript writing, collection and/or assembly of
related data, data analysis; S.C., A.B.C., C.K.: manuscript writing, collection
and/or assembly of related data, data analysis; T.N.C., M.K.: data analysis
and interpretation, manuscript writing, conception and design, project
supervision, final editing and manuscript oversight; C.V.B.: experimental
work, collection and/or assembly of data, data analysis and interpretation,
manuscript writing, conception and design, project supervision, final
editing and manuscript oversight.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.

1. Meschia JF, Brott T. Ischaemic stroke. Eur J Neurol. 2018;25:35-40.
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke
statistics-2017 update: a report from the American Heart Association.
Circulation. 2017;135:e146-e603.
3. Go AS, Mozafarian D, Roger V, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American
Heart Association. Circulation. 2014;129:399-410.
4. Kim JS. tPA helpers in the treatment of acute ischemic stroke: are
they ready for clinical use? J Stroke. 2019;21:160-174.
5. Pianta S, Lee JY, Tuazon JP, et al. A short bout of exercise prior to
stroke improves functional outcomes by enhancing angiogenesis.
Neuromolecular Med. 2019. https://doi.org/10.1007/s12017-01908533-x. [Epub ahead of print].
6. Primiani CT, Vicente AC, Brannick MT, et al. Direct aspiration versus
stent retriever thrombectomy for acute stroke: a systematic review
and meta-analysis in 9127 patients. J Stroke Cerebrovasc Dis. 2019;28:
1329-1337.
7. Hess DC, Borlongan CV. Stem cells and neurological diseases. Cell
Prolif. 2008;41(suppl 1):94-114.
8. Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard
for human ES and iPS cells. J Cell Physiol. 2009;220(1):21-29.
9. Liska MG, Crowley MG, Borlongan CV. Regulated and unregulated
clinical trials of stem cell therapies for stroke. Transl Stroke Res. 2017;
8:93-103.
10. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great
migration of bone marrow-derived stem cells toward the ischemic
brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95:213-228.
11. Borlongan CV. Bone marrow stem cell mobilization in stroke: a “bonehead” may be good after all! Leukemia. 2011;25:1674-1686.
12. Gorabi AM, Kiaie N, Barreto GE, et al. The therapeutic potential of
mesenchymal stem cell-derived exosomes in treatment of neurodegenerative diseases. Mol Neurobiol. 2019;56:8255–8276.
13. Staff NP, Jones DT, Singer W. Mesenchymal stromal cell therapies for
neurodegenerative diseases. Mayo Clin Proc. 2019;94:892-905.
14. Chen D, Fu W, Zhuang W, Lv C, Li F, Wang X. Therapeutic effects of
intranigral transplantation of mesenchymal stem cells in rat models of
Parkinson's disease. J Neurosci Res. 2017;95:907-917.
15. Levy YS, Bahat-Stroomza M, Barzilay R, et al. Regenerative effect of
neural-induced human mesenchymal stromal cells in rat models of
Parkinson's disease. Cytotherapy. 2008;10:340-352.
16. Sadan O, Bahat-Stromza M, Barhum Y, et al. Protective effects of
neurotrophic factor-secreting cells in a 6-OHDA rat model of
Parkinson disease. Stem Cells Dev. 2009;18:1179-1190.
17. Boido M, Piras A, Valsecchi V, et al. Human mesenchymal stromal cell
transplantation modulates neuroinflammatory milieu in a mouse
model of amyotrophic lateral sclerosis. Cytotherapy. 2014;16:10591072.
18. Forostyak S, Homola A, Turnovcova K, Svitil P, Jendelova P,
Sykova E. Intrathecal delivery of mesenchymal stromal cells protects
the structure of altered perineuronal nets in SOD1 rats and amends
the course of ALS. STEM CELLS. 2014;32:3163-3172.
19. Marconi S, Bonaconsa M, Scambi I, et al. Systemic treatment with
adipose-derived mesenchymal stem cells ameliorates clinical and
pathological features in the amyotrophic lateral sclerosis murine
model. Neuroscience. 2013;248:333-343.

Downloaded from https://academic.oup.com/stcltm/article/9/2/203/6406779 by University of South Florida user on 21 June 2022

the NCS-01 cells was within 3 days post-MCAO, beneficial effects were

RE FE RE NCE S

220

41. Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15:5372-5378.
42. Barber PA, Zhang J, Demchuk AM et al. Why are stroke patients
excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001 24;56(8):1015–1020.
43. Li Y, Chopp M, Chen J, et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke
in adult mice. J Cereb Blood Flow Metab. 2000;20:1311-1319.
44. Gisselsson L, Toresson H, Ruscher K, Wieloch T. Rho kinase inhibition
protects CA1 cells in organotypic hippocampal slices during in vitro
ischemia. Brain Res. 2010;1316:92-100.
45. Deboux C, Ladraa S, Cazaubon S, et al. Overexpression of CD44 in neural precursor cells improves trans-endothelial migration and facilitates
their invasion of perivascular tissues in vivo. PLoS One. 2013;8:e57430.
46. Ahn BJ, Le H, Shin MW, Bae SJ, et al. Ninjurin1 enhances the basal motility and transendothelial migration of immune cells by inducing protrusive membrane dynamics. J Biol Chem. 2014;289:21926-21936.
47. Scandaglia M, Benito E, Morenilla-Palao C, et al. Fine-tuned SRF
activity controls asymmetrical neuronal outgrowth: implications for
cortical migration, neural tissue lamination and circuit assembly. Sci
Rep. 2015;5:17470.
48. Bang OY, Kim EH. Mesenchymal stem cell-derived extracellular vesicle therapy for stroke: challenges and progress. Front Neurol. 2019;
10:211.
49. Gancheva MR, Kremer KL, Gronthos S, Koblar SA. Using dental pulp
stem cells for stroke therapy. Front Neurol. 2019;10:422.
50. Zarriello S, Neal EG, Kaneko Y, Borlongan CV. T-regulatory cells confer increased myelination and stem cell activity after stroke-induced
white matter injury. J Clin Med. 2019;8(4):pii: E537.
51. Yong KW, Choi JR, Mohammadi M, Mitha AP, Sanati-Nezhad A,
Sen A. Mesenchymal stem cell therapy for ischemic tissues. Stem Cells
Int. 2018;2018:1-11.
52. Russo E, Nguyen H, Lippert T, Tuazon J, Borlongan CV, Napoli E.
Mitochondrial targeting as a novel therapy for stroke. Brain Circ.
2018;4:84-94.
53. Laso-García F, Diekhorst L, Gómez-de Frutos MC, et al. Cell-based
therapies for stroke: promising solution or dead end? Mesenchymal
stem cells and comorbidities in preclinical stroke research. Front Neurol. 2019;10:332.
54. Zhang Y, Yu S, Tuazon JP, et al. Neuroprotective effects of human
bone marrow mesenchymal stem cells against cerebral ischemia are
mediated in part by an anti-apoptotic mechanism. Neural Regen Res.
2019;14:597-604.
55. Nguyen H, Zarriello S, Coats A, et al. Stem cell therapy for neurological disorders: a focus on aging. Neurobiol Dis. 2019;126:85-104.

SUPPORTING INF ORMATION
Additional supporting information may be found online in the
Supporting Information section.

How to cite this article: Kaneko Y, Lee J-Y, Tajiri N, et al.
Translating intracarotid artery transplantation of bone
marrow-derived NCS-01 cells for ischemic stroke: Behavioral
and histological readouts and mechanistic insights into stem
cell therapy. STEM CELLS Transl Med. 2020;9:203–220.
https://doi.org/10.1002/sctm.19-0229

Downloaded from https://academic.oup.com/stcltm/article/9/2/203/6406779 by University of South Florida user on 21 June 2022

20. Bae JS, Jin HK, Lee JK, Richardson JC, Carter JE. Bone marrowderived mesenchymal stem cells contribute to the reduction of
amyloid-β deposits and the improvement of synaptic transmission in
a mouse model of pre-dementia Alzheimer's disease. Curr Alzheimer
Res. 2013;10:524-531.
21. Lee HJ, Lee JK, Lee H, et al. Human umbilical cord blood-derived
mesenchymal stem cells improve neuropathology and cognitive
impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. Neurobiol Aging. 2012;33:588-602.
22. Acosta SA, Tajiri N, Hoover J, Kaneko Y, Borlongan CV. Intravenous
bone marrow stem cell grafts preferentially migrate to spleen and
abrogate chronic inflammation in stroke. Stroke. 2015;46:2616-2627.
23. Borlongan CV. Concise review: stem cell therapy for stroke patients:
are we there yet? STEM CELLS TRANSLATIONAL MEDICINE. 2019;8:983–988.
24. Eckert MA, Vu Q, Xie K, et al. Evidence for high translational potential
of mesenchymal stromal cell therapy to improve recovery from ischemic stroke. J Cereb Blood Flow Metab. 2013;33:1322-1334.
25. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen
Med. 2010;5:933-946.
26. Kocsis JD, Honmou O. Bone marrow stem cells in experimental
stroke. Prog Brain Res. 2012;201:79-98.
27. Rowart P, Erpicum P, Detry O, et al. Mesenchymal stromal cell therapy in ischemia/reperfusion injury. J Immunol Res. 2015;2015:
602597.
28. Toyoshima A, Yasuhara T, Kameda M, et al. Intra-arterial transplantation of allogeneic mesenchymal stem cells mounts neuroprotective
effects in a transient ischemic stroke model in rats: analyses of therapeutic time window and its mechanisms. PLoS One. 2015;10:
e0127302.
29. Shen LH, Li Y, Chen J, et al. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow
Metab. 2007;27:6-13.
30. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke. 2007;38:817-826.
31. Chen X, Li Y, Wang L, et al. Ischemic rat brain extracts induce human
marrow stromal cell growth factor production. Neuropathology. 2002;
22:275-279.
32. Liu X, Ye R, Yan T, et al. Cell based therapies for ischemic stroke: from
basic science to bedside. Prog Neurobiol. 2014;115:92-115.
33. Stonesifer C, Corey S, Ghanekar S, Diamandis Z, Acosta SA,
Borlongan CV. Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms. Prog
Neurobiol. 2017;158:94-131.
34. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell
transplantation in stroke patients. Ann Neurol. 2005;57:874-882.
35. Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of
intravenous autologous mesenchymal stem cell transplantation in
patients with ischemic stroke. STEM CELLS. 2010;28:1099-1106.
36. Malagelada C, Xifró X, Badiola N, et al. Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygenglucose deprivation. Stroke. 2004;35:2396-2401.
37. Borlongan CV, Kaneko Y, Maki M, et al. Menstrual blood cells display
stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells Dev. 2010;19:
439-452.
38. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;
30:42-59.
39. Ishikawa H, Tajiri N, Vasconcellos J, et al. Ischemic stroke brain sends
indirect cell death signals to the heart. Stroke. 2013;44:3175-3182.
40. Borlongan CV, Hida H, Nishino H. Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery.
Neuroreport. 1998;9:3615-3621.

KANEKO ET AL.

